The Selection and Use of Essential Medicines - WHO Technical Report Series, No. 920: 7. Recommendations: 7.5 Future priorities

The Selection and Use of Essential Medicines - WHO Technical Report Series, No. 920
(2003; 137 pages)

Índice de contenido

1. Introduction
2. Open session
3. Update on current activities
	3.1 Dissemination of the previous report of the Expert Committee (including the 12th Model List)
	3.2 The twenty-fifth anniversary of the WHO Model List of Essential Medicines
	3.3 The WHO model formulary
	3.4 Review of the New Emergency Health Kit
	3.5 Review of essential medicines for reproductive health
	3.6 Report of an ad hoc Advisory Committee on priority vaccines
	3.7 The WHO Essential Medicines Library
	3.8 Promoting rational use of essential medicines
		3.8.1 Update on activities to contain antimicrobial resistance
		3.8.2 Guidelines for drugs and therapeutic committees
		3.8.3 WHO database on rational drug use studies
4. Changes made in revising the Model List
	4.1 Applications for additions
		4.1.1 Amodiaquine
		4.1.2 Azithromycin
		4.1.3 Ibuprofen (paediatric formulation)
		4.1.4 Insulin semilente
		4.1.5 Miconazole nitrate buccal tablets
		4.1.6 Misoprostol
		4.1.7 Valaciclovir
	4.2 Applications for deletions
		4.2.1 Ethinylestradiol + levonorgestrel tablets (50µg + 250µg, pack of four)
		4.2.2 Nonoxynol
	4.3 Applications for addition of information
		4.3.1 Anti-leprosy medicines
	4.4 Other changes
		4.4.1 Oral rehydration salts
		4.4.2 Streptokinase
5. Reviews of sections of the Model List
	5.1 "Fast-track" procedure for deleting items from the Model List
	5.2 Review of core versus complementary listing of medicines
	5.3 Review of the use of the square box symbol (including a review of the corticosteroids)
	5.4 Review of the antihypertensive medicines
6. Priorities for future reviews
7. Recommendations
	7.1 Additions, deletions and other changes to the Model List
	7.2 Core versus complementary listing of medicines
	7.3 Use of the square box symbol (including review of the corticosteroids
	7.4 Review of the antihypertensive medicines
	7.5 Future priorities
References
Annex 1 The 13th WHO Model List of Essential Medicines
Annex 2 The Anatomical Therapeutic Chemical (ATC) classification system¹
Alphabetical list of essential medicines (with ATC classification code numbers)
Selected WHO Publications of Related Interest

7.5 Future priorities

1. The Committee recommended that the following items be presented for fast-track deletion at its next meeting: ether, colchicine, clonazepam, niclosamide, pyrantel, triclabendazole, oxamniquine, imipenem + cilastatin, nalidixic acid, spectinomycin, levofloxacin, thioacetazone + isoniazid, diethyltoluamide, ergotamine, polygeline, factor VIII and factor IX concentrates, isoprenaline, procainam-ide, quinidine, nifedepine, topical sun protection agent, antihaemorrhoidal local anaesthetic, astringent and anti-inflamma-tory preparations, atropine (in section 17.5 Antispasmodic medicines), codeine (in section 17.7.2 Antidiarrhoeal (symptomatic) medicines), medroxyprogesterone acetate (in section 18.3.1 Hormonal contraceptives and section 18.7 Progestogens), silver nitrate, ergometrine, salbutamol (in section 22.2 Antioxytocics), aminophyl-line, cromoglicic acid, theophylline, calcium gluconate (in section 27 Vitamins and minerals) and sodium fluoride.

2. The Committee recommended that these items be marked in the Model List with the following footnote:

The public health relevance and/or efficacy and/or safety of this item has been questioned and its continued inclusion in the Model List will be reviewed at the next meeting of the Expert Committee.